Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
AssigneeKiora Pharmaceuticals, Inc.
InventorsStefan Sperl, Lisa Plasser
Life of this patent
Estimating the term…
Abstract
The present disclosure provides salts of 3-(2,3,5,6-tetrafluoro-3′-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid. The present disclosure also provides pharmaceutical compositions comprising salts of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a salt of the invention.
Claims20
A compound of Formula I
- wherein Y* is
- vi) a single atom cation with a +1 charge;
- vii) a single atom cation with a +2 charge;
- viii) a carb oxyalkyl ammonium cation, optionally substituted with one or more hydroxyl or amino groups;
- ix) a dialkylammonium cation, optionally substituted with one or more hydroxyl groups;
- or
- x) an alkylammonium cation, optionally substituted with one or more hydroxyl groups.
3-22. (canceled)
A method of treating an inflammatory disease or an autoimmune disease comprising administering to a subject in need thereof an effective amount of pharmaceutically acceptable composition comprising:
- a) a compound of Formula I
- wherein Y* is
- i) a single atom cation with a +1 charge;
- ii) a single atom cation with a +2 charge;
- iii) a carboxyalkylammonium cation, optionally substituted with one or more hydroxyl or amino groups;
- iv) a dialkylammonium cation, optionally substituted with one or more hydroxyl groups;
- or
- v) an alkylammonium cation, optionally substituted with one or more hydroxyl groups;
- and
- b) a pharmaceutically acceptable excipient, carrier, diluent, or combination thereof.
A compound of Formula I
- wherein Y* is a potassium ion.
A compound of Formula I
- wherein Y* is a pharmaceutically acceptable cation, wherein the bioavailability of the compound of Formula I in a dog is greater than 20%.
A compound of Formula I
- wherein Y* is a pharmaceutically acceptable cation, wherein the solubility of the compound of Formula I is greater than 1 mg/ml at pH 6.4 to 6.5, at 37° C., in a FaSSIF media.
Dependencies are inferred from the claim text.